View Document Preview and Link Open Document File Size: 682,17 KB Share Result on Facebook
City Document / / Company AEs / Bracco Diagnostics Inc. / Clinical Safety Experience Bracco Diagnostics Inc. / / Continent Asia / Europe / / Country Switzerland / Romania / Hungary / Estonia / Slovenia / Bulgaria / Cyprus / Latvia / Poland / Norway / United States / Iceland / Canada / Slovakia / Malta / China / Singapore / Lithuania / South Korea / India / Czech Republic / / Event FDA Phase / / IndustryTerm intravascular imaging agents / cardiac and noncardiac applications / low solubility gas / literature search / / MedicalCondition pulmonary route / Documented Coronary Artery Disease / COPD / chest pain / headache / acute myocardial infarctions / nausea / anaphylaxis / Fatigue / Diffuse Interstitial Pulmonary Fibrosis / hypersensitivity / cardiovascular diseases / Congestive Heart Failure / hypertension / flushing / pulmonary hemodynamics / dyspnea / apparent hypersensitivity / pulmonary function / Chronic Obstructive Pulmonary Disease / cardiovascular disease / Pulmonary Hypertension / serious hypersensitivity / pain / dizziness flushing / myocardial infarction / coronary artery disease / dizziness / back pain nausea/vomiting / severe chronic obstructive pulmonary disease / / MedicalTreatment heart catheterization / / Organization Food and Drug Administration / Commission of the European Communities / Drug Safety and Risk Management Advisory Committee / SonoVue administration / European Union / Advisory Committee / Cardiovascular and Renal Drugs Advisory Committee / / Position physician / Executive / / Product Microspheres Injectable suspension / Optison / Definity / USCAs / SonoVue / Europe / / Technology Ultrasound / pharmacokinetics / CAD / Medical Imaging / / URL www.fda.gov/ohrms/dockets/AC/08/briefing/2008-4369b105.pdf / http / SocialTag 
SonoVue® Reports Integrated WWM&RA Advisory Committee Briefing Document SonoVue® (sulfur hexafluoride microbubbles)